Skip to content

Clinical study on the efficacy and safety of high calcium CPP casein phosphopeptide in promoting bone health and height development in children

Clinical study on the efficacy and safety of high calcium CPP casein phosphopeptide in promoting bone health and height development in children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104222
Enrollment
Unknown
Registered
2025-06-12
Start date
2025-06-13
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Growth deficiency in children

Interventions

Experimental group:Intervention Name: Natural Doctor? High Calcium CPP casein phosphopeptide Drink

Sponsors

Department of Child Health, Guangdong Maternal and Child Health Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
4 Years to 10 Years

Inclusion criteria

Inclusion criteria: 1. Children aged 4-10 years, regardless of gender (girls aged 4-9 years, boys aged 4-10 years); 2. The height is at the P10-P25 level of people of the same age and sex; 3. Bone age <= actual age +6 months (atlas method); 4. Prepuberty (Stage 1 Tanner); 5. No previous history of growth hormone therapy; 6. Birth weight/height for gestational age (P10-P90).

Exclusion criteria

Exclusion criteria: 1. Children with hypocalcemia with serum calcium below 2.13 mmol/L (8.5 mg/dl); 2. Liver or kidney dysfunction; Chronic systemic disease or immune deficiency; 3. has been diagnosed with another growth disorder (GH deficiency, Turner syndrome, Noonan syndrome, Laron syndrome, or growth disorder caused by hypothyroidism); 4. Children identified as obese based on BMI; 5. Impaired glucose regulation or diabetes mellitus; 6. Congenital bone malformations, scoliosis or claudication; 7. Mental illness; 8. Allergic to the ingredients of the investigational product; 9. Participated in other clinical trials within 3 months; 10. Receiving medication or other hormone therapy that may interfere with GH secretion or function; 11. For other reasons, the researchers considered it unsuitable for inclusion in the study.

Design outcomes

Primary

MeasureTime frame
Height of children;Weight of children;bone mineral density;

Countries

China

Contacts

Public ContactWu Jieling

epartment of Child Health, Guangdong Maternal and Child Health Hospital

jieling3861@163.com+86 136 0045 6180

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026